Manufacturing Process Development of Tegoprazan as a Potassium-Competitive Acid Blocker (P-CAB)

Jae Hong Kweon; Hyungjin Shin; Min Kyoung Lee; Sung Ah Lee; Pargat Singh; Kyeongwon Moon; In Su Kim

doi:10.1021/acs.oprd.4c00005

Manufacturing Process Development of Tegoprazan as a Potassium-Competitive Acid Blocker (P-CAB)

Jae Hong Kweon
, Hyungjin Shin
, Min Kyoung Lee
, Sung Ah Lee
, Pargat Singh
, Kyeongwon Moon
, In Su Kim

Department of Pharmacy

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Tegoprazan, a selective potassium-competitive acid blocker, was approved in 2018 in the Republic of Korea for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis (EE), and nonerosive reflux disease (NERD). The complexity of tegoprazan, which contains a 4,6-disubstituted 1H-benzo[d]imidazole core and a chiral chromanol moiety, makes it a challenging molecule to prepare on a commercial scale. An efficient and economical route of the key intermediates and a much improved end-game for tegoprazan were developed.

Original language	English
Pages (from-to)	1159-1169
Number of pages	11
Journal	Organic Process Research and Development
Volume	28
Issue number	4
DOIs	https://doi.org/10.1021/acs.oprd.4c00005
State	Published - 19 Apr 2024

Keywords

Asymmetric hydrogenation
Manufacturing process
Mitsunobu etherification
Potassium-competitive acid blocker
Tegoprazan

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/acs.oprd.4c00005

Cite this

@article{400df8742c674f618ba4aa611da385d7,

title = "Manufacturing Process Development of Tegoprazan as a Potassium-Competitive Acid Blocker (P-CAB)",

abstract = "Tegoprazan, a selective potassium-competitive acid blocker, was approved in 2018 in the Republic of Korea for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis (EE), and nonerosive reflux disease (NERD). The complexity of tegoprazan, which contains a 4,6-disubstituted 1H-benzo[d]imidazole core and a chiral chromanol moiety, makes it a challenging molecule to prepare on a commercial scale. An efficient and economical route of the key intermediates and a much improved end-game for tegoprazan were developed.",

keywords = "Asymmetric hydrogenation, Manufacturing process, Mitsunobu etherification, Potassium-competitive acid blocker, Tegoprazan",

author = "Kweon, \{Jae Hong\} and Hyungjin Shin and Lee, \{Min Kyoung\} and Lee, \{Sung Ah\} and Pargat Singh and Kyeongwon Moon and Kim, \{In Su\}",

note = "Publisher Copyright: {\textcopyright} 2024 American Chemical Society.",

year = "2024",

month = apr,

day = "19",

doi = "10.1021/acs.oprd.4c00005",

language = "English",

volume = "28",

pages = "1159--1169",

journal = "Organic Process Research and Development",

issn = "1083-6160",

publisher = "American Chemical Society",

number = "4",

}

TY - JOUR

T1 - Manufacturing Process Development of Tegoprazan as a Potassium-Competitive Acid Blocker (P-CAB)

AU - Kweon, Jae Hong

AU - Shin, Hyungjin

AU - Lee, Min Kyoung

AU - Lee, Sung Ah

AU - Singh, Pargat

AU - Moon, Kyeongwon

AU - Kim, In Su

PY - 2024/4/19

Y1 - 2024/4/19

N2 - Tegoprazan, a selective potassium-competitive acid blocker, was approved in 2018 in the Republic of Korea for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis (EE), and nonerosive reflux disease (NERD). The complexity of tegoprazan, which contains a 4,6-disubstituted 1H-benzo[d]imidazole core and a chiral chromanol moiety, makes it a challenging molecule to prepare on a commercial scale. An efficient and economical route of the key intermediates and a much improved end-game for tegoprazan were developed.

AB - Tegoprazan, a selective potassium-competitive acid blocker, was approved in 2018 in the Republic of Korea for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis (EE), and nonerosive reflux disease (NERD). The complexity of tegoprazan, which contains a 4,6-disubstituted 1H-benzo[d]imidazole core and a chiral chromanol moiety, makes it a challenging molecule to prepare on a commercial scale. An efficient and economical route of the key intermediates and a much improved end-game for tegoprazan were developed.

KW - Asymmetric hydrogenation

KW - Manufacturing process

KW - Mitsunobu etherification

KW - Potassium-competitive acid blocker

KW - Tegoprazan

UR - https://www.scopus.com/pages/publications/85187344395

U2 - 10.1021/acs.oprd.4c00005

DO - 10.1021/acs.oprd.4c00005

M3 - Article

AN - SCOPUS:85187344395

SN - 1083-6160

VL - 28

SP - 1159

EP - 1169

JO - Organic Process Research and Development

JF - Organic Process Research and Development

IS - 4

ER -

Manufacturing Process Development of Tegoprazan as a Potassium-Competitive Acid Blocker (P-CAB)

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this